GENE EXPRESSION MARKERS FOR PREDICTING RESPONSE TO INTERLEUKIN-6 RECEPTOR-INHIBITING MONOCLONAL ANTIBODY DRUG TREATMENT

摘要

This invention provides methods, compositions, and kits relating to gene product biomarkers where gene expression levels are correlated with therapeutic response of rheumatoid arthritis patients to treatment with an IL-6 receptor antagonist, such as an IL6 antibody. The methods, compositions, and kits of the invention can be used to identify rheumatoid arthritis patients who are likely, or not likely, to respond to IL-6 receptor antagonist treatments.